Yazar "Kobat, Mehmet Ali" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology
    (Elsevier Science Inc, 2014) Aydin, Suna; Aydin, Suleyman; Kobat, Mehmet Ali; Kalayci, Mehmet; Eren, Mehmet Nesimi; Yilmaz, Musa; Kuloglu, Tuncay
    Irisin is a muscle-secreted protein. Cardiac muscle produces more irisin than skeletal muscle in response to acute exercise, and is associated with myocardial infarction (MI) in an experimental model induced by isoproterenol in rats. The timing and significance of its release in patients with acute myocardial infarction (AMI) needs further investigation. We have studied the relationship between serum/saliva irisin concentration and AMI in humans. Serum and saliva samples were taken within 3 days of admission in 11 patients with AMI and in 14 matched controls. Salivary gland irisin was detected immunohistochemically, and serum and saliva levels were measured by ELISA. The three major paired salivary glands (submandibular, sublingual and parotid) produce and release irisin into saliva. Troponin-I, CK, CK-MB concentrations in the AMI group gradually increased from up to 12 h, while saliva and serum irisin gradually decreased from up to 48 h, compared with the control group (P < 0.05). After 12 h, troponin-I, CK, CK-MB started to decrease, while saliva and serum irisin started to increase at 72 h. Serum irisin levels correlated with age, while troponin I, CK-MB, and CK were correlated and with saliva irisin in AMI patients. Besides cardiac troponin and CK-MB, irisin adds new diagnostic information in AMI patients, and the gradual decrease of saliva/serum irisin over 48 h could be a useful biomarker. (c) 2014 Elsevier Inc. All rights reserved.
  • [ X ]
    Öğe
    Effects of Systemic Propranolol Application on the New Bone Formation in Periimplant Guided Bone Regeneration
    (Uab Stilus Optimus, 2021) Gunes, Nedim; Gul, Mehmet; Dundar, Serkan; Artas, Gokhan; Kobat, Mehmet Ali; Tekin, Samet; Bozoglan, Alihan
    Objectives: The aim of this experimental animal study was to evaluate the effects of systemic propranolol on new bone formation in peri-implant bone defects. Material and Methods: Implant slots were created 4 mm long and 2.5 mm wide. After the titanium implants were placed in the sockets, 2 mm defects were created in the neck of the implants. Bone grafts were placed in these defects. Then the rats were randomly divided into three equal groups: control (n = 8), propranolol dose-1 (PRP-1) (n = 8), and propranolol dose-2 (PRP-2) (n = 8) groups. In the control group, the rats received no further treatment during the eight-week experimental period after the surgery. The rats in the PRP-1 and PRP-2 groups were given 5 mg/kg and 10 mg/kg propranolol, respectively, every three days for the eight-week experimental period after the surgery. At the end of the experimental period, the rats were euthanized. Blood serum was collected for biochemical analysis, and the implants and surrounding bone tissues were used for the histological analysis. Results: There were no significant differences in the histological analysis results and the biochemical parameters (alkaline phosphatase, calcium, creatinine and phosphorus) of the groups (P > 0.05). Also, in the test groups, there was numerically but not statistically more new bone formation detected compared with the controls. Conclusions: Within the limitations of this study, propranolol did not affect the new bone formation in peri-implant defects.
  • Küçük Resim
    Öğe
    An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER*-2 study design
    (Türk Kardiyoloji Derneği, 2015) Ertaş, Faruk; Kaya, Hasan; Yıldız, Abdulkadir; Davutoğlu, Vedat; Kiriş, Abdulkadir; Dinç, Lale; Kafes, Habibe; Avcı, Anıl; Çalapkorur, Bekir; Ertaş, Gökhan; Gül, Mehmet; Ay, Nuray Kahraman; Bulur, Serkan; Durukan, Mine; Eren, Murat; İlhan, İbrahim; Küçük, Murathan; Özpelit, Ebru; Şimşek, Hakkı; Uçar, F. Mehmet; Yıldız, Ahmet; Şahin, Yıldıray; Ayhan, Erkan; Çağlayan, Emre; Güngör, Hasan; Özyurtlu, Ferhat; Şen, Nihat; Vatan, Bülent; Vatansever, Fahriye; Kobat, Mehmet Ali; Temiz, Ahmet; Taylan, Gökay; Dönmez, İbrahim; Erkuş, M. Emre; Söylemez, Selami; Zengin, Halit; Gündüz, Mahmut; Tuncez, Abdullah; Karavelioğlu, Yusuf; Gökdeniz, Tayyar; Koza, Yavuzer; Aktop, Ziyaeddin; Katlandur, Hüseyin; Özer, Pelin Karaca; Yüksel, Murat; Acet, Halit; Çil, Habib; Alan, Sait; Toprak, Nizamettin
    Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).